HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
NCT ID: NCT06238284
Last Updated: 2024-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2024-01-26
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics
NCT05251883
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
NCT04520295
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
NCT03614689
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
NCT06564428
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
NCT02610218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cervical Cancer Group
no intervention
Since it is a retrospective study, no intervention is needed.
Endometrial Cancer Group
no intervention
Since it is a retrospective study, no intervention is needed.
Ovarian Cancer Group
no intervention
Since it is a retrospective study, no intervention is needed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
Since it is a retrospective study, no intervention is needed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women aged 18-75
* The expected survival time is greater than 12 weeks
* KPS \> 60, ECOG score is 0-2
* All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up
Exclusion Criteria
* Suffering from other malignant tumors in the past 5 years
* Patients who are not suitable for this study according to the investigator's judgment
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chongqing University Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CQ-HER2-GYN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.